The battle against cancer continues – that’s not news. Neither is the fact that 42 percent of Canadians will be diagnosed with cancer at some point in our lifetime. A 2026 Canadian cancer statistics study published in the Canadian Medical Association Journal estimates a whopping 254,100 new cancer cases this year alone. 

These statistics are just one part of the ongoing story of what’s happening in Canada on the health front. But there’s actually good news to share: So far in 2026, advances in precision medicine, immunotherapy, early detection and AI, for example, are raising new possibilities. Here are the cutting edge developments we’ve been following that prove there’s hope on the horizon. 

Early Detection

In June, BC Cancer’s Hereditary Cancer Program shared news of a blood test that shows which side of the family cancer-causing mutations come from, helping relatives manage inherited cancer risk while also reducing the need for unnecessary testing. The groundbreaking Parent-of-Origin Aware Genomic Analysis (POAga) uses a blood sample to pinpoint (with 98 percent accuracy) which parent the cancer-causing variants in genes – like BRCA1 and BRCA 2 – were inherited from. This hereditary cancer-testing technology is key – determining which side of the family carries the mutation improves the effectiveness of genetic screening and relieves one side of a family from worry and stress. A pilot study for POAga looked at pancreatic cancer and blood samples from nine patients determined hereditary risk for 188 relatives. This knowledge means those relatives can access genetic testing, get earlier screening and take advantage of preventative care that can help reduce their risk of cancer. 

Precision Medicine

A Health Canada announcement in September is a gamechanger in precision oncology research. (Precision oncology helps physicians determine more personalized treatments for patients based on their genes and specific cancer cells.) Marjorie Michel, Canada’s minister of health, announced an $80 million investment over four years to the Terry Fox Research Institute (TFRI), one of the organizations behind the collection of data on cancerous tumours from more than 16,000 patients. The goals of the institute, which established the Marathon of Hope Cancer Centres Network, are to learn why some people respond to certain cancer treatments better than others and to ultimately provide more personalized care for patients. TFRI and the Network is set to add 11,000 new cases to its data repository, all to analyze and return vital information on genes to inform care. They’re also matching Health Canada’s investment, unlocking $160 million in funding. 

Immunotherapy

Cancer cells camouflage themselves in the body, hiding from T-cells, which fight bacteria, viruses and abnormal cancerous cells. This summer, scientists at the University of Calgary developed a treatment called GCAR1 to deal with these hidden cells. The doctors take a sample of the patient’s T-cells from their blood, then scientists genetically engineer the cells by giving them a radar (called the Chimeric Antigen Receptor, or CAR) that spots cancer cells. Then, T-cells are put back into the patient’s body to look for and destroy tumours. CAR T-cell therapies have been around for a decade, but they have generally been successful fighting blood cancers and not solid tumours (like ones found in the breast or kidneys, for example). UCalgary’s GCAR1 is designed to attack those difficult-to-treat tumours and has shown promise in mouse models and early human testing is now underway. 

Artificial Intelligence

Tracking how cancer changes over time has been incredibly difficult, but Vancouver’s Genetrack Biolabs and the Michael Smith Genome Sciences Centre have developed a cancer-testing platform called GenTraceDx. This technology allows physicians to track how their patients’ cancer changes over time, arming them with data so they can make more informed treatment decisions. Dubbed “the world’s first living cancer diagnostic,” it analyzes specific tumour data as new trials and drugs are introduced, giving patients the opportunity to take advantage of the latest treatments. “GenTraceDx transforms cancer testing from a static snapshot into a living system that evolves with each patient’s journey,” said Dr. June Wong, CEO of Genetrack Biolabs, in a press release. It is “designed to ensure that patients and physicians remain connected to the most current and relevant treatment opportunities throughout the entire cancer journey.” 

Plus, Promising New Developments in …

#1 Brain Cancer

Published in the journal Neuron in January, research from scientists at the Hospital for Sick Children in Toronto and McMaster University in Hamilton, Ont., shows they’ve found a way to slow the growth of glioblastoma, the most aggressive form of brain cancer, which is currently incurable. What’s more, they have discovered an existing medication for HIV, called maraviroc, which holds promise as a new treatment option for patients. “Glioblastoma isn’t just a mass of cancer cells, it’s an ecosystem. By decoding how these cells talk to each other, we’ve found a vulnerability that could be targeted with a drug that’s already on the market,” said Dr. Sheila Singh, a professor of surgery at McMaster and the co-senior author of the study, in a press release. 

#2 Pancreatic Cancer 

According to the Canadian Cancer Society, pancreatic cancer is expected to be the third-leading cause of cancer death in 2026, with 7,500 people being diagnosed and 6,500 dying from the disease this year. One recent finding that offers hope when it comes to targeted therapies for patients comes from the Research Institute of the McGill University Health Centre in Montreal. Scientists at the institute have identified a protein called HSPE1 that pancreatic cancer cells rely on to multiply and survive. This discovery is a big step in the continued research and development of targeted therapies. The HSPE1 protein is vital for cancer cells mitochondria – it helps cells protect themselves and keeps them alive. Without it, the cells stop functioning and self-destruct. The team also found that the survival of cancer cells relies on two parallel signalling pathways. When they blocked those pathways, tumour growth slowed. In a press release, one of the study’s authors, Dr. Jean-Jacques Lebrun, said, “We have demonstrated that simultaneously targeting both pathways is much more effective than blocking just one or the other, thereby revealing a new combined therapeutic strategy for pancreatic cancer.” 

Also new in the fight against this cancer is a drug called daraxonrasib, which, in clinical trials in the U.S., nearly doubled overall survival rates for advanced pancreatic cancer compared to traditional chemotherapy. Some Canadian oncologists are calling it one of the biggest breakthroughs in pancreatic cancer. Daraxonrasib was approved by the FDA in August for patients with metastatic pancreatic adenocarcinoma; as of the end of September, it had yet to be sent to Health Canada for review.